Kyverna Therapeutics Inc.

NASDAQ: KYTX · Real-Time Price · USD
3.53
-0.01 (-0.28%)
At close: Aug 15, 2025, 3:59 PM
3.58
1.42%
After-hours: Aug 15, 2025, 06:09 PM EDT

Kyverna Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
96.62M 34.65M 37.73M 76.07M
Short-Term Investments
189.36M 22.9M 13.59M n/a
Long-Term Investments
n/a n/a 554K 552K
Other Long-Term Assets
3.39M 3.92M 678K 41K
Receivables
n/a n/a n/a n/a
Inventory
n/a n/a n/a n/a
Other Current Assets
4.62M 3.12M 1.93M 1.02M
Total Current Assets
290.6M 60.66M 53.25M 77.09M
Property-Plant & Equipment
10.66M 10.61M 12.44M 7.81M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
14.04M 14.53M 13.67M 8.4M
Total Assets
304.64M 75.19M 66.92M 85.49M
Account Payables
4.62M 4.36M 1.45M 773K
Deferred Revenue
n/a n/a 7.66M 6M
Short-Term Debt
3.94M n/a n/a n/a
Other Current Liabilities
943K 9.77M 6.82M 7.2M
Total Current Liabilities
33.76M 19.86M 11.95M 15.93M
Long-Term Debt
n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a 120.68M 78K
Total Long-Term Liabilities
4.3M 6.16M 128.97M 115.81M
Total Liabilities
38.06M 26.02M 140.92M 131.74M
Total Debt
8.24M 9.08M 10.56M 5.55M
Common Stock
n/a n/a n/a n/a
Retained Earnings
-263.52M -136.04M -75.68M -46.78M
Comprehensive Income
105K 4K -26K n/a
Shareholders Equity
266.59M 49.18M -74M -46.25M
Total Investments
189.36M 22.9M 13.59M 552K